Status:
COMPLETED
Immunohistochemistry Role in Better Prognosis of Endometrial Carcinoma Patients
Lead Sponsor:
Zagazig University
Conditions:
Endometrial Cancer
Eligibility:
FEMALE
36-72 years
Phase:
NA
Brief Summary
The incidence of endometrial cancer (EC) is increasing .Different risk classifications are used to direct the primary and adjuvant therapy. The European Society for Medical Oncology - European Society...
Eligibility Criteria
Inclusion
- aged 36 -72 years;
- Previously diagnosed with endometrial carcinoma;
- Histological Type of the tumor;
- Myometrial Invasion;
- lymph Node Invasion;
- Cervical Invasion;
- Biomarkers expression.
Exclusion
- Lack of tumor tissue in tissue block
Key Trial Info
Start Date :
January 12 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2022
Estimated Enrollment :
96 Patients enrolled
Trial Details
Trial ID
NCT06148129
Start Date
January 12 2019
End Date
March 1 2022
Last Update
November 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig university
Zagazig, Ash Sharqia Governorate, Egypt, 44519